{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:09:21Z","timestamp":1762902561834,"version":"3.45.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cjcopen.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.cjco.2020.07.016","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T12:21:14Z","timestamp":1595506874000},"page":"641-651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical Discussions in Antithrombotic Therapy Management in Patients With Atrial Fibrillation: A Delphi Consensus Panel"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-5630","authenticated-orcid":false,"given":"Nicola","family":"Mumoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Amellone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Augello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosima","family":"Cloro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"D\u2019Alleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo Di","family":"Ascenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egidio","family":"Imbalzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Masala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziano","family":"Riccioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giosu\u00e8","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Sciatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Tondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Toso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elio","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Vizzardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giosu\u00e8","family":"Mascioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2020.07.016_bib1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2020.07.016_bib2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2020.07.016_bib3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2020.07.016_bib4","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2020.07.016_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cjco.2020.07.016_bib6","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi survey technique","volume":"32","author":"Hasson","year":"2000","journal-title":"J\u00a0Adv Nurs"},{"key":"10.1016\/j.cjco.2020.07.016_bib7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2010.12.001","article-title":"Methods of formal consensus in classification\/diagnostic criteria and guideline development","volume":"41","author":"Nair","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.cjco.2020.07.016_bib8","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2020.07.016_bib9","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2020.07.016_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1160\/TH16-10-0757","article-title":"Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants","volume":"117","author":"Raparelli","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cjco.2020.07.016_bib11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.repc.2014.01.013","article-title":"The impact of dosing frequency on medication adherence in chronic cardiovascular disease: systematic review and meta-analysis","volume":"33","author":"Caldeira","year":"2014","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.cjco.2020.07.016_bib12","first-page":"747","article-title":"Values and preferences of physicians and patients with nonvalvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention","volume":"32","author":"Andrade","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2020.07.016_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1477-7525-7-30","article-title":"Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q)","volume":"7","author":"Prins","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.cjco.2020.07.016_bib14","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.cjco.2020.07.016_bib15","article-title":"Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Patients and Investigators. Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2-VASc Scores: findings from the ORBIT-AF I and II Registries","volume":"7","author":"Jackson","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjco.2020.07.016_bib16","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.hrthm.2015.07.017","article-title":"Patients with atrial fibrillation and CHA2DS2-VASc score 1: \"To anticoagulate or not to anticoagulate? That is the question!","volume":"12","author":"Patti","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjco.2020.07.016_bib17","article-title":"Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation)","volume":"6","author":"Patti","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjco.2020.07.016_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.arr.2018.10.006","article-title":"Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation","volume":"49","author":"Kato","year":"2019","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.cjco.2020.07.016_bib19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jacep.2015.02.019","article-title":"Age-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: The EORP-AF General Pilot Registry (EURObservational Research Programme-Atrial Fibrillation)","volume":"1","author":"Fumagalli","year":"2015","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.cjco.2020.07.016_bib20","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial","volume":"5","author":"Kato","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjco.2020.07.016_bib21","first-page":"3238","article-title":"Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis","volume":"36","author":"Andreotti","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2020.07.016_bib22","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1586\/14779072.2013.818819","article-title":"Personalizing oral anticoagulant treatment in patients with atrial fibrillation","volume":"11","author":"Capranzano","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.cjco.2020.07.016_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11739-017-1624-x","article-title":"Real-world evidence with apixaban for stroke prevention in patients with nonvalvular atrial fibrillation in Germany: a retrospective study (REASSESS)","volume":"12","author":"Coleman","year":"2017","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.cjco.2020.07.016_bib24","doi-asserted-by":"crossref","first-page":"j510","DOI":"10.1136\/bmj.j510","article-title":"Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"356","author":"Nielsen","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.cjco.2020.07.016_bib25","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction","volume":"69","author":"Yao","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2020.07.016_bib26","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: The ORBIT-AF II Registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2020.07.016_bib27","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2020.07.016_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/pharmaceutics9030036","article-title":"Augmented renal clearance in critical illness: an important consideration in drug dosing","volume":"9","author":"Mahmoud","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cjco.2020.07.016_bib29","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.medin.2018.02.004","article-title":"Augmented renal clearance: Much more is better?","volume":"42","author":"Tomasa Irriguible","year":"2018","journal-title":"Med Intensiva"},{"key":"10.1016\/j.cjco.2020.07.016_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacc.2016.04.031","article-title":"Dabigatran versus warfarin in relation to renal function in patients with atrial fibrillation","volume":"68","author":"Del-Carpio Munoz","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2020.07.016_bib31","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.116.024666","volume":"135","author":"Lindner","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2020.07.016_bib32","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.amjmed.2017.04.015","article-title":"Renal function considerations for stroke prevention in atrial fibrillation","volume":"130","author":"Fanikos","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.cjco.2020.07.016_bib33","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.mayocp.2018.06.018","article-title":"Influence of renal function on the pharmacokinetics, pharmacodynamics, efficacy, and safety of non-vitamin K antagonist oral anticoagulants","volume":"93","author":"Weir","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cjco.2020.07.016_bib34","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jacc.2018.05.066","article-title":"Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety","volume":"72","author":"Lee","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2020.07.016_bib35","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1161\/STROKEAHA.118.021387","article-title":"Impact of renal function on outcomes with edoxaban in real-world patients with atrial fibrillation","volume":"49","author":"Yu","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.cjco.2020.07.016_bib36","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1038\/s41598-019-43224-4","article-title":"Comparison of once-daily administration of edoxaban and rivaroxaban in Asian patients with atrial fibrillation","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.cjco.2020.07.016_bib37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2020.07.016_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.15420\/aer.2017.50.1","article-title":"The significance of drug-drug and drug-food interactions of oral anticoagulation","volume":"7","author":"Vranckx","year":"2018","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"10.1016\/j.cjco.2020.07.016_bib39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH09-08-0580","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary intervention\/ stenting","volume":"103","author":"Lip","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cjco.2020.07.016_bib40","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjco.2020.07.016_bib41","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2007.02.027","article-title":"Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial","volume":"49","author":"Manoukian","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2020.07.016_bib42","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/jama.2013.1556","article-title":"Association between bleeding events and in-hospital mortality after percutaneous coronary intervention","volume":"309","author":"Chhatriwalla","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2020.07.016_bib43","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/eurheartj\/ehr204","article-title":"Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2020.07.016_bib44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCINTERVENTIONS.113.001150","article-title":"Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions","volume":"7","author":"Capodanno","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cjco.2020.07.016_bib45","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2020.07.016_bib46","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2020.07.016_bib47","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2020.07.016_bib48","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2020.07.016_bib49","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2020.07.016_bib50","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2019.1880","article-title":"Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials","volume":"4","author":"Lopes","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjco.2020.07.016_bib51","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jth.14001","article-title":"Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants","volume":"16","author":"Testa","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cjco.2020.07.016_bib52","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.amjmed.2016.05.041","article-title":"Evaluation of dose-reduced direct oral anticoagulant therapy","volume":"129","author":"Barra","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.cjco.2020.07.016_bib53","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1161\/01.STR.14.5.688","article-title":"Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study","volume":"14","author":"Hart","year":"1983","journal-title":"Stroke"},{"key":"10.1016\/j.cjco.2020.07.016_bib54","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.34.10.1285","article-title":"Cerebral ischemia and atrial fibrillation: prospective study","volume":"34","author":"Kelley","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.cjco.2020.07.016_bib55","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1161\/hs1001.097093","article-title":"Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial","volume":"32","author":"Saxena","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.cjco.2020.07.016_bib56","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1161\/STROKEAHA.115.008891","article-title":"Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: The RAF Study","volume":"46","author":"Paciaroni","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.cjco.2020.07.016_bib57","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/ene.12577","article-title":"Association of improved outcome in acute ischaemic stroke patients with atrial fibrillation who receive early antithrombotic therapy: analysis from VISTA","volume":"22","author":"Abdul-Rahim","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.cjco.2020.07.016_bib58","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/ijs.12150","article-title":"Types of stroke recurrence in patients with ischemic stroke: a substudy from the PRoFESS trial","volume":"9","author":"Toni","year":"2014","journal-title":"Int J Stroke"},{"key":"10.1016\/j.cjco.2020.07.016_bib59","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/europace\/eux316","article-title":"Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry","volume":"20","author":"Ruiz Ortiz","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.cjco.2020.07.016_bib60","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/jnnp-2018-318890","article-title":"Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study","volume":"90","author":"Wilson","year":"2019","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cjco.2020.07.016_bib61","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group","volume":"349","author":"[No authors listed]","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2020.07.016_bib62","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(13)70079-6","article-title":"Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials","volume":"12","author":"Whiteley","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cjco.2020.07.016_bib63","article-title":"Early Recurrence and Major Bleeding in Patients with Acute Ischemic Stroke and Atrial Fibrillation Treated with Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study","volume":"6","author":"Paciaroni","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjco.2020.07.016_bib64","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1253\/circj.CJ-18-0067","article-title":"Two-year outcomes of anticoagulation for acute ischemic stroke with nonvalvular atrial fibrillation\u2014SAMURAI-NVAF Study","volume":"82","author":"Yoshimura","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.cjco.2020.07.016_bib65","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/ana.25489","article-title":"Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation","volume":"85","author":"Seiffge","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cjco.2020.07.016_bib66","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.12.038","article-title":"The dose of direct oral anticoagulants and stroke severity in patients with acute ischemic stroke and nonvalvular atrial fibrillation","volume":"27","author":"Kato","year":"2018","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.cjco.2020.07.016_bib67","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.07.036","article-title":"Resolving thrombus in the left atrial appendage by edoxaban treatment after acute ischemic stroke: report of 2 cases","volume":"25","author":"Saito","year":"2016","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.cjco.2020.07.016_bib68","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacep.2016.01.004","article-title":"Prevalence of left atrial thrombus detection by transesophageal echocardiography: a comparison of continuous non-vitamin K antagonist oral anticoagulant versus warfarin therapy in patients undergoing catheter ablation for atrial fibrillation","volume":"2","author":"Frenkel","year":"2016","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.cjco.2020.07.016_bib69","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4330\/wjc.v11.i2.84","article-title":"Prevalence and clinical characteristics associated with left atrial thrombus detection: apixaban","volume":"11","author":"Whiteside","year":"2019","journal-title":"World J Cardiol"},{"key":"10.1016\/j.cjco.2020.07.016_bib70","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.hrthm.2017.12.005","article-title":"Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: comparison of dabigatran, rivaroxaban, and apixaban","volume":"15","author":"Wu","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjco.2020.07.016_bib71","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2017.07.048","article-title":"NOACs and atrial fibrillation: incidence and predictors of left atrial thrombus in the real world","volume":"249","author":"Bertaglia","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjco.2020.07.016_bib72","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10840-018-0432-1","article-title":"Left atrial thrombus despite continuous direct oral anticoagulant or warfarin therapy in patients with atrial fibrillation: insights into rates and timing of thrombus resolution","volume":"53","author":"Wu","year":"2018","journal-title":"J\u00a0Interv Card Electrophysiol"},{"key":"10.1016\/j.cjco.2020.07.016_bib73","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013623","article-title":"Dabigatran as an alternative for atrial thrombosis resistant to rivaroxaban: a case report","volume":"97","author":"Sun","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cjco.2020.07.016_bib74","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/ccr3.933","article-title":"A\u00a0left atrial appendage thrombus that developed during prophylactic low-dose dabigatran treatment resolved after switching to apixaban","volume":"5","author":"Koyama","year":"2017","journal-title":"Clin Case Rep"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X20301116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X20301116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:03:45Z","timestamp":1762902225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X20301116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":74,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S2589790X20301116"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2020.07.016","relation":{},"ISSN":["2589-790X"],"issn-type":[{"type":"print","value":"2589-790X"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Discussions in Antithrombotic Therapy Management in Patients With Atrial Fibrillation: A Delphi Consensus Panel","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2020.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Canadian Cardiovascular Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}